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Abstract
Background: Enterovirus 71 (EV71) is a great disease burden across the whole world, particularly in Southeast Asia.
However, in recent decades, the pathogenesis of severe EV71 infection was not well understood. This study was
aimed to investigate the correlation between the presence of viremia and the clinical severity of EV71 infection.
Methods: We organized a prospective cohort study and enrolled laboratory-confirmed EV71 cases in six tertiary
care hospitals in Taiwan during the EV71 epidemic from 2011 to 2012. Blood samples were collected once in the
acute stage, on the first day of admission. We used real-time RT-PCR to detect EV71 viremia. Demographical and
clinical data were collected and the clinical severity was categorized into four grades. Data analysis was performed
to identify the risk factors of viremia and the correlation between viremia and clinical severity of EV71 infection.
Results: Of the total 224 enrolled patients, 59 (26%) patients were confirmed to have viremia. Two-thirds (68%) of
viremic cases were detected within the first three days of infection. Viremia occurred more frequently in children
under the age of one year old (odds ratios [OR] 4.82, p < 0.001) but the association between the presence of viremia
and complicated EV71 infection was not found (OR 1.02, p = 0.96). In the viremia group, patients had significantly
more severe complications if viremia was detected after the third day of disease onset (26% vs. 5%, p = 0.03).
Conclusions: Viremia occurred more frequently in children under the age of one year and viremia detected
beyond three days after the onset of disease correlated with more severe disease in EV71 patients.
Keywords: Enterovirus, Viremia, Severe EV71 infection
Background
In recent decades, enterovirus infection has accounted
for several outbreaks and has become a heavy burden of
public health and socioeconomics in both developing
and developed countries [1]. Among the numerous sero-
types of enterovirus, enterovirus 71 (EV71) infection has
especially drawn great attention because of the poor
prognosis of severe infection [2,3], possible neurologic
sequelae [4-6] and high transmissibility [1,7].
In Southeast Asia, outbreaks of EV71 infection have be-
come a serious public health problem [1-3,8,9]. In Taiwan,
EV71 has become one of the most significant epidemic
diseases in children after the first documented large out-
break in 1998 [2,4-6,10,11]. EV71 epidemics recur in
Taiwan in intervals of three to four years and generate a
great disease burden [12-16].
After investigating the characteristics of the transmis-
sion of EV71, the professionals in Taiwan’s Enterovirus
Ad Hoc Committee and the Taiwan Centers for Disease
Control designed several health policies, such as both
physician and virological laboratory surveillance systems
and hand-washing education program to control the epi-
demics of EV71. The above policies limited the outbreak
and the impact of EV71 infection and reduced the num-
bers of fatal EV71 infection [15,17]. As for the treatment
of EV71 infection, a stage-based management decreased
the mortality rate in EV71 patients as well [18]. However,
regarding the pathogenesis of severe EV71 infection,
* Correspondence: lychang@ntu.edu.tw
1Department of Pediatrics, National Taiwan University Hospital and College
of Medicine, National Taiwan University, Taipei, Taiwan
Full list of author information is available at the end of the article
© 2014 Cheng et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Cheng et al. BMC Infectious Diseases 2014, 14:417
http://www.biomedcentral.com/1471-2334/14/417
research has not identified the mechanism causing severe
EV71 infection and its complications [19]. Host factors,
environmental factors and viral factors have been investi-
gated for a long time but no conclusion has been achieved
[13,19-22]. This problem impedes the progress of the de-
velopment of a more focused treatment strategy. Antiviral
agents, such as pleconaril, have been studied in some in-
vitro researches and clinical trials, but the efficacy of treat-
ing EV71 has not been confirmed [23,24]. On the other
hand, intravenous immunoglobulin was also used to treat
severe EV71 infection based on its ability of virus
neutralization and anti-inflammation, but the effectiveness
was only based on retrospective researches [8,18]. It is
crucial for the development of EV71-specific treatment to
test whether a new antiviral drug or an immunomodulator
is effective. The study of EV71 viremia might provide
more details about the pathogenesis of severe EV71 infec-
tion and contribute to further interventional studies. Al-
though a previous study in animal model discussed the
kinetics of viremia and clinical diseases [25], no similar
study has been conducted on humans. As a result, we
aimed to investigate whether viremia is correlated to the
clinical severity of EV71 infection and seek to provide




According to the laboratory-based surveillance system of
Taiwan CDC, the baseline proportion of EV71 among all
the enterovirus isolates from patients with enterovirus
infections was about 2% but the proportion increased
sharply between 2011 and 2012 and peaked in 2012
(45%) [26]. As a result, we considered the years 2011
and 2012 as epidemic years for EV71. We prospectively
enrolled the EV71 cases hospitalized in six tertiary hos-
pitals during the epidemic of EV71 from 2011 to 2012.
The geographical distribution of patients included north-
ern, central and southern Taiwan. All the patients were
less than 18 years old and were suspected to have an
EV71 infection according to their clinical manifestation
such as hand, foot, and mouth disease (HFMD), herpan-
gina or febrile illness without obvious focus during en-
terovirus epidemics. The study was approved by the
institutional review board at National Taiwan University
Hospital. The written informed consent was obtained
from the parents of the studied children.
EV71 infection of clinically-suspected cases was con-
firmed on the basis of the following laboratory methods:
positive virus isolation of EV71, and/or positive EV71 iden-
tification by pan-enterovirus real-time RT-PCR followed by
molecular serotyping. We collected the basic demographic
data including age and gender, the date of the onset of dis-
ease, the date of blood sampling for EV71 virologic test,
and their clinical manifestations and outcomes. According
to their clinical manifestation and outcome, the clinical
severity of the patients with EV71 infection was classified
according to the following four categories at the hospital
discharge [15]:
Grade 1: Uncomplicated HFMD, herpangina or
febrile illness,
Grade 2: Mild central nervous system (CNS)
involvement including myolonic jerk alone or
aseptic meningitis,
Grade 3: Severe CNS involvement, such as encephalitis,
encephalomyelitis or polio-like syndrome, but without
cardiopulmonary failure.
Grade 4: CNS involvement complicated by
cardiopulmonary failure.
Blood samples for basic laboratory tests including
complete blood count and virologic test were collected
only once on the first day of admission. Real-time RT-
PCR was used for detection of virus RNA in the blood
sample to confirm the presence of viremia and its mag-
nitude according to the protocol mentioned as below.
Virus isolation and serotyping
Throat swabs were submitted for virus isolation. Sam-
ples were inoculated into human embryonic fibroblast
(MRC-5), LLC-MK2, HEp-2, and RD cell cultures. If en-
teroviral cytopathic effect involved more than 50% of the
cell monolayer, the cells were scraped and indirect fluor-
escent antibody staining with panenteroviral antibody
(Chemicon International, Inc., Temecula, CA) was per-
formed to identify the enterovirus. These isolates would be
further serotyped to be EV71 by an immunofluorescent
assay using EV71-specific mono-clonal antibodies against
viruses (Chemicon International, Inc., Temecula, CA).
Pan-enterovirus real-time RT-PCR
Viral RNA extraction from throat swabs and sera was
performed using an isolation kit (RNA extraction kit,
Qiagen, Hilden, Germany), and reverse transcription was
performed with first strand cDNA synthesis kit for RT-
PCR (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s directions. Real time RT-PCR for pan-
enterovirus was performed with the primers of 5′-TCC
TCCGGCCCCTGAATG-3′ and 5′-AATTGTCACCATAA
GCAGCCA-3′, the probe of 6FAM-AACCGACTACTT
TGGGTGTCCGTGTTTCXT-PH. The detection limitation
(sensitivity) was ≤ 10 copies of in vitro transcribed RNA for
pan-enterovirus real-time RT-PCR [27].
If the result of pan-enterovirus real-time RT-PCR was
positive, molecular serotyping was subsequently per-
formed. The cDNA was sent for semi-nested PCR with
primers used in a previous report [27], the PCR product
Cheng et al. BMC Infectious Diseases 2014, 14:417 Page 2 of 8
http://www.biomedcentral.com/1471-2334/14/417
was purified, and auto-sequencing was performed with
the forward primer on a 3730 ABI automatic sequencer
with BigDye Terminator v3.1 Termination Cycle Se-
quencing Ready Reaction Kit (Applied Biosystems,
Perkin-Elmer, Foster City, CA). The serotype was iden-
tified to EV71 by comparing the partial VP1 sequence
to those recorded in the public gene database contain-
ing VP1 sequences for the strains of EV71.
Statistical analysis
Descriptive analysis was performed for the demographic
data and other characteristics of the EV71 patients. Viral
load was presented as log10 copies/ml. In univariate ana-
lysis, Student’s t test and Mann–Whitney U test were
used for continuous variables and chi-square test or
Fisher’s exact test was used for categorical variables,
when appropriate, to identify the factors associated with
viremia and the risk factors of complicated EV71 infec-
tion. In multivariate analysis, multiple logistic regression
analysis was used. A two-tailed p value of 0.05 was con-
sidered statistically significant. Data were maintained in
Microsoft Excel, Mac, 2011 (Bellevue, WA) and analyzed
by using Stata 12.0 (Stata Corp, College Station, TX).
Results
Basic characteristics
From 2011 to 2012, we totally enrolled 224 patients with
their sera collected in this study. The median age was
2.71 years old (range 0 to 15 years), and male to female
ratio was 1.49 (Table 1). Eighty-eight (39%) patients with
laboratory-confirmed EV71 infection had an uncompli-
cated disease (Grade 1), such as HFMD, herpangina or
simple febrile illness and 61 percent had at least one
complication noticed, mostly mild CNS involvement
(101 of 224 patients, 45%, grade 2). Most patients with
mild CNS involvement had myoclonic jerk alone (100 of
101 patients, 99%) while only one patient had aseptic
meningitis. Thirty-five of 224 patients (16%) had severe
complication of EV71 infection (grade 3 and grade 4).
Among total 224 patients, most patients were discharged
smoothly without sequelae. There were only three pa-
tients who had neurologic sequelae, and there were only
two deaths (Table 1).
EV71 viremia
Sera of 224 EV71 cases were collected during acute stage
and real-time RT-PCR was performed for enterovirus to
detect EV71 viremia. The day of blood sampling for
EV71 viremia ranged from the first day after the onset of
disease to the seventh day, mostly on the third day (me-
dian four days).
Fifty-nine of 224 cases (26%) had positive PCR results
and viremia was confirmed. The percentage of con-
firmed viremia was highest on the first day of illness and
viremia was lower in patients sampled after day 3
(Figure 1). Two-thirds of viremic cases were detected
within the first three days of disease (68% vs. 32%, re-
spectively, p < 0.001). The viral load ranged from 0.88
log10 copies/mL to 6.99 log10 copies/mL (median 3.46
log10 copies/mL). The viral load was highest when the
blood was sampled between the third and fourth day
after disease onset, and the viral load was lower if the
blood was sampled later (Figure 2). The viral load sampled
during day 1 to day 3 was significantly higher than the viral
load sampled on day 4 or later (median 3.68 vs. 3.13 log10
copies/mL, p = 0.01 with Mann–Whitney U test).
Children under one year of age were more likely to
have viremia than children aged one or older (odds ra-
tios [OR] 4.82, p < 0.001), while gender and other symp-
toms and signs, such as skin rash, oral ulcer, fever and
the duration of fever, did not influence the presence or
the magnitude of viremia (Table 2). Viremia did not have
a significant effect on the distribution of clinical severity
of EV71 cases. After we adjusted other factors in multi-
variate analysis, age under one year and the day of blood
sampling were the only two significantly risk factors for
EV71 viremia (Table 3).





Age (median with range, years) 2.71 (0–15)
≤ 3 y/o 102 46%




Clinical Severity (Grade 1 to 4)
Uncomplicated diseasea 88 39%
Myoclonic jerk or aseptic meningitis 101 45%
Severe CNS involvementb without
cardiopulmonary failure
22 10%




Complete recovery 219 98%
With sequelaec 3 1%
Death 2 1%
aUncomplicated cases includes uncomplicated HFMD, herpangina or
febrile illness.
bSevere CNS involvement includes encephalitis, encephalomyelitis or
polio-like syndrome.
cAmong the three patients with sequelae, one patient had cervical mye1itis and
thoracic spine arachnoiditis and had flaccid paralysis of right arm, another had
rhombencephalitis complicated with left arm paralysis and ventilator-dependence
after dishcharge, the other had paralysis of left arm and lower limbs and also
needed non-invasive positive pressure ventilation after discharge.
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Factors associated with clinical severity
In univariate analysis, no correlation between the pres-
ence of viremia and the clinical severity of EV71 infec-
tion was found (Table 4). No significant difference of the
percentage of viremic cases was found between patients
with mild diseases (grade 1 to 2) and with severe
complications (grade 3 to 4) (27.5% and 20%, respect-
ively, p = 0.41). The risk factor for complicated EV71 dis-
eases was fever (OR 7.33, p < 0.001) and fever over
3 days (OR 2.49, p = 0.002). Higher viral load did not
correlate with more severe clinical disease. Those pa-
tients with complicated EV71 infection were younger
than those with uncomplicated disease (median age 2.60
vs. 3.08 years, p = 0.06). The multivariate analysis adjust-
ing age, gender, and clinical symptoms revealed similar
results (Table 5).
For those who had severe complications (grade 3 to 4),
the percentage of viremic cases did not decrease beyond
three days of illness compared to those who had milder
EV71 diseases (grade 1 to 2) (Figure 3). Contrarily, in
the viremia group, patients had significantly more severe
complications if their viremia was detected after the
third day of disease onset (26% vs. 5%, p = 0.03).
Discussion
In our study, 224 patients with laboratory-confirmed
EV71 infection were enrolled. Approximately one-fourth
of the EV71 patients had viremia detected in acute stage
of disease. To our knowledge, this is the first study to in-
vestigate the correlation between EV71 viremia and the
clinical severity of EV71 infection and we found that
prolonged viremia was associated with the risk of severe




























Day of illness 1 2 3 4 5 6 7
Total cases with blood 
sampling
3 23 58 45 49 31 15
Case number of viremic 
patients
3 19 18 10 7 2 0
Proportion of viremia 100% 83% 31% 22% 14% 6% 0%
Figure 1 The proportion of viremic patients with EV71 infection grouped by day of illness.





















Figure 2 Distribution of the levels of EV71 viremia in blood
samples grouped by days after disease onset. Day 1 indicates
the first day of disease. The horizontal line presents the median viral
load. Mann–Whitney U test was used for comparison between the
serum viral loads sampled within and beyond three days after
disease onset respectively.
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As for EV71 infection, the classical clinical manifest-
ation, disease course and possible impacts on neurologic
and cognitive function has been documented thoroughly
in previous studies [4,21,22,28,29]. In our study, patients
with complicated EV71 infection accounted for about 60%
of total EV71 cases. Most of them had only myoclonic jerk.
Compared to previous epidemiology data [4,7,30,31], the
proportion of cases with severe CNS involvement was
lower in our cohort. This reduction may be related to dif-
ferent cohorts or different hospital setting.
According to previous retrospective studies, the age of
patients is an important risk factor of severe EV71 infec-
tion [16,32]. Our study demonstrated similar tendency,
that is, younger children were more vulnerable to have
CNS involvement. We also found that children with age
under one had a significantly higher rate of viremia,
which might be correlated to more complicated clinical
manifestations.
Most of the cases with viremia in this study were de-
tected before the third day of disease. This tendency is
compatible to the clinical observation about the mean
duration of a prodromal stage with fever before the fol-
lowing neurologic complications caused by EV71 [4].
After the third day of disease onset, the proportion of
patients with viremia decreased to around one-fourth al-
though the proportion of complicated disease remained
at the similar level. No viremia was detected after the
seventh day of disease onset even if these patients had
Table 2 Clinical characteristics of patients with and without EV71 viremia
No Viremia (n = 165) Viremia (n = 59) p valuea
Age (median with range, years) 2.95 (0–14) 2.12 (0–15) 0.05
≤ 1 years old 10 (6%) 14 (24%) <0.001
> 1 years old 155 (94%) 45 (76%)
Gender 0.43
Male 106 (64%) 34 (42%)
Female 59 (36%) 25 (58%)
Skin rash 155 (94%) 58 (98%) 0.30
Oral ulcer 162 (98%) 55 (93%) 0.08
Feverb 152 (92%) 52 (88%) 0.43
Duration of fever (mean ± SD, days) 2.99 ± 1.85 2.38 ± 1.99 0.07
Clinical Severity (Grade 1 to 4)
Uncomplicated disease 65 (39%) 23 (39%) 0.54d
Complicated disease 100 (61%) 36 (61%)
Myoclonic jerk or aseptic meningitis 72 (44%) 29 (49%)
Severe CNS involvement without cardiopulmonary failure 17 (10%) 5 (8%)
Severe CNS involvement with cardiopulmonary failure 11 (7%) 2 (3%)
Sample day for PCR testc
≤ 3 days 44 (27%) 40 (68%) <0.001
> 3 days 121 (73%) 19 (32%)
Viral loadc (median with range, log10 copies/mL)
≤ 3 days 3.68 (0.88 - 6.99) 0.01
> 3 days 3.13 (1.56 – 4.20)
Values expressed as n(%), unless otherwise indicated.
aThe chi-square test was used for categorical variables and the Mann–Whitney test was used for comparison of the viral load.
bFever was defined as any body temperature elevation over 38 degrees Celsius.
cCaterorized as days after disease onset.
dStatistical analysis was performed for the difference between patients with uncomplicated and complicated diseases.
Table 3 Multivariate analysis for risk factors of EV71
viremia
Odds ratio 95% CI p value
Age <1 year 4.27 1.45 - 12.59 0.008
Sex (Male) 0.98 0.82 - 1.18 0.84
Skin rash 0.70 0.21 - 2.40 0.57
Fevera 7.81 0.40 - 152.76 0.18
Oral ulcer 0.34 0.02- 5.48 0.45
Grade 2 to 4 EV71 disease 1.16 0.54 - 2.47 0.70
Day of illness on sampling (day) 0.39b 0.28 - 0.54 <0.001
aFever was defined as any body temperature over 38 degrees Celsius.
bThe value represents the change in odds ratio per day after disease onset.
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persistent clinical symptoms, indicating that the reso-
lution of enterovirus viremia occurred most within seven
days and that deterioration of the clinical disease beyond
seven days was rare. In animal models, the viral kinetics
in the systemic EV71 infection in rhesus monkeys also
revealed a similar pattern compared to our study [25].
Additionally, the percentages of patients with CNS in-
volvement in patients with or without viremia were simi-
lar and we did not find the positive correlation between
the presence of viremia and the clinical severity of EV71
infection. Viremia is an interesting topic of virus infec-
tion and many researchers have taken great efforts to es-
tablish correlation between the clinical manifestation
and the duration or the magnitude of viremia in several
viral diseases. In some viral infections, such as the
Epstein–Bar virus and cytomegalovirus disease [33-35],
the presence or the magnitude of viremia may be able to
predict clinical severity, while in other cases, such as
dengue virus, norovirus and hantavirus, the presence of
viremia usually only indicated the active stage of disease,
but did not absolutely predict the clinical severity [36-39].
The observation in our study suggested that EV71 might be
more similar to the later ones.
A possible explanation is that EV71 is considered to
be a neurotropic infectious microorganism [40] and the
presence of viremia is not the most crucial step for its
severe infection. Viremia may only occur in a certain
stage of EV71 infection for a short period and most re-
solve spontaneously soon afterwards. Another support-
ing evidence is that the virus can be detected from
throat swab and rectal swab [19,32,41], which are the
primary sites of EV71 infection and it is the cellular
tropism that contributes to the clinical presentations
and the following complications, for example, myoclonic
jerk and other CNS involvement in EV71 infection.
Furthermore, we found that the proportion of detected
viremic cases in patients with severe complications (grade 3
Table 4 Predictive factors of complicated diseases in patients with EV71 infection
Uncomplicated EV71 infection
(Grade 1) (n = 88)
Complicated EV71 infection
(Grade 2 to 4) (n = 136)
p valuea
Age (median with range, years) 3.08 (0–15) 2.60 (0–14) 0.06
Gender
Male 56 (64%) 84 (62%) 0.89
Female 32 (36%) 52 (38%)
Feverb 72 (82%) 132 (97%) <0.001
Fever > 3 days 34 (39%) 83 (61%) 0.002
Skin rash 86 (97%) 124 (94%) 0.21
Oral ulcer 85 (97%) 132 (97%) 1.00
Viremia
Yes 23 (26%) 36 (26%) 0.96
No 65 (74%) 100 (74%)
Viral load (median with range, log10 copies/mL) 3.34 (0.88 - 6.99) 3.50 (1.29 - 6.51) 0.80
Values expressed as n(%), unless otherwise indicated.
aThe chi-square and Fisher’s exact test was used for categorical variables, and the Mann–Whitney test was used for comparison of the viral load.
bFever was defined as any body temperature over 38 degrees Celsius.
Table 5 Multivariate analysis of risk factors of
complicated EV71 disease (grade 2 to 4)
Odds ratio 95% CIs p value
Age <1 year 2.57 0.87 - 7.62 0.09
Sex (Male) 0.99 0.86 - 1.15s 0.92
Skin rash 0.29 0.05 - 1.54 0.15
Fevera 5.63 1.74 - 18.28 0.001
Oral ulcer 1.91 0.31 - 11.74 0.48
Day of illness on sampling (day) 1.05b 0.84 - 1.31 0.66
Viremia 1.26 0.61 - 2.59 0.54
aFever was defined as any body temperature over 38 degrees Celsius.
bThe value represents the change in odds ratio per day after disease onset.




















Figure 3 The percentage of viremia within and beyond three
days after disease onset in patients who had mild diseases
(grade 1 to 2) and severe complications (grade 3 to 4).
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to 4) remained similar after the third day of disease while
the proportion of viremia decreased in those who had mild
diseases (grade 1 to 2). The finding suggested the viremia
might persist longer in those who had severe diseases and
thus their risk of systemic involvement and complications
increased. In addition, the proportion of patients with se-
vere CNS involvement and cardiopulmonary failure in-
creased in those patients whose viremia was detected after
the third day of disease. That is to say, a much higher virus
burden, prolonged viremic phase or the consequent im-
munologic reactions might be the principle mechanism of
the severe complications of disease rather than viremia
alone. Previous studies suggested that the most severe form
of EV71 infection causing pulmonary edema might result
from the overreaction of immune system and consequent
cytokine storm [19,42]. Besides, a prospective cohort study
performed in Sarawak during three EV71 outbreaks over
seven years and our previous study [2,8], showing that a
fever for three days or longer was associated with neuro-
logical complications, may also support this hypothesis. On
the other hand, a previous pathogenesis study performed in
rhesus monkey has suggested CNS invasion was correlated
with severe CNS diseases with pulmonary edema and the
viral loads in the CNS were parallel to the viremia. As a re-
sult, a prolonged viremia may increase the viral load in the
CNS and is more likely to lead to more severe CNS disease
and further cardiopulmonary failure [25].
Nevertheless, the clinical severity of EV71 infection
may be multifactorial and is not determined only by the
presence of viremia. Either the different virulence of dif-
ferent genotypes, host factors and other socioeconomic
factors [13,19-22] may contribute to the severe compli-
cation and sequelae of EV71 infection as well.
There are some limitations in our study. First, we only
collected blood samples for PCR test at one time point in
each patient and it is difficult to describe the kinetics and
the duration of viremia. A kinetic data could provide more
information about the influence of viremia on the clinical
manifestation, disease severity and the whole course of
EV71 infection. It is also impossible to determine the peak
viral load of individuals and this limitation makes it more
difficult to clarify the definite relationship between the mag-
nitude of viremia and the clinical manifestation. Second,
most patients in our cohort had only uncomplicated disease
or myoclonic jerk and the proportion of severe CNS com-
plications or further cardiopulmonary failure was relatively
low. Because the epidemics of non-polio enterovirus oc-
curred almost every year in Taiwan, the decreased severity
of EV71 infection may result from partial cross-protection
from previous enterovirus infection by different serotypes
or genotypes [43]. Only 15.6% of patients with EV71 infec-
tion in this study had severe complications. The sample size
was not large enough to establish the correlation between
viremia and severe complications of EV71 infection.
Conclusions
In summary, our study found that viremia occurred
more frequently in children under the age of one year
and viremia detected beyond three days after the onset
of disease correlated with more severe disease in EV71
patients. Our findings may shed a light on the identifica-
tion of the role of viremia for the pathogenesis of severe
EV71 infection, but further studies targeted at the inter-
action between the magnitude, the kinetics of viremia
and other host factors in patients with severe EV71
infection will be required.
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